Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 4:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,083 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Chemotherapy Symptoms Clear all
Withdrawn Not applicable Interventional Accepts healthy volunteers

Bimatoprost Ophthalmic Solution in Increasing Eyebrow and Eyelash Growth in Patients Who Have Undergone Chemotherapy for Breast Cancer and in Healthy Participants

NCT00999557
View directory record Official record
Conditions
Alopecia, Breast Cancer
Interventions
bimatoprost ophthalmic solution, placebo
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Sep 11, 2026, 4:14 PM EDT
Completed Phase 1 Interventional

Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia

NCT00054236
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
anti-thymocyte globulin, filgrastim, cyclophosphamide, fludarabine phosphate, umbilical cord blood transplantation, methylprednisolone
Biological · Drug · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Up to 120 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 26, 2020 · Synced Sep 11, 2026, 4:14 PM EDT
Completed Phase 4 Interventional Results available

Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting

NCT01432015
View directory record Official record
Conditions
Ovarian Cancer, Uterine Cancer
Interventions
fosaprepitant, aprepitant, Oral Placebo, IV placebo
Drug · Other
Lead sponsor
Gynecologic Oncology Associates
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Sep 11, 2026, 4:14 PM EDT
Terminated Phase 4 Interventional

A Phase IV Trial of Cesamet™ Given With Standard Antiemetic Therapy for Chemotherapy-induced Nausea and Vomiting

NCT00418678
View directory record Official record
Conditions
Nausea and Vomiting
Interventions
Cesamet
Drug
Lead sponsor
Veeda Oncology
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 1, 2010 · Synced Sep 11, 2026, 4:14 PM EDT
Not listed Phase 2Phase 3 Interventional

Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma

NCT00003338
View directory record Official record
Conditions
Lymphoma
Interventions
immunoscintigraphy, technetium Tc 99m epratuzumab
Procedure · Radiation
Lead sponsor
Gilead Sciences
Industry
Eligibility
16 Years to 120 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Cuyahoga Falls, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2021 · Synced Sep 11, 2026, 4:14 PM EDT
Terminated Phase 2 Interventional Results available

Megestrol Acetate in Treating Weight Loss or Anorexia in Young Patients With Malignancies Who Are Undergoing Radiation Therapy and/or Chemotherapy

NCT01200602
View directory record Official record
Conditions
Anorexia, Weight Changes
Interventions
megestrol acetate, clinical observation
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
Up to 21 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 24, 2015 · Synced Sep 11, 2026, 4:14 PM EDT
Completed Phase 3 Interventional Results available

Phase III Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer

NCT02111577
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
DCVAC/PCa, Placebo
Biological
Lead sponsor
SOTIO a.s.
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
58
States / cities
Mobile, Alabama • Chandler, Arizona • Scottsdale, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2021 · Synced Sep 11, 2026, 4:14 PM EDT
Completed Phase 1 Interventional

Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer

NCT00104975
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
alemtuzumab, therapeutic allogeneic lymphocytes, fludarabine phosphate, melphalan, tacrolimus, thiotepa, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Sep 11, 2026, 4:14 PM EDT
Completed Phase 3 Interventional

Comparison of Antiemetic Drugs in Preventing Delayed Nausea After Chemotherapy in Patients With Cancer

NCT00020657
View directory record Official record
Conditions
Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
dolasetron mesylate, granisetron hydrochloride, ondansetron, prochlorperazine, quality-of-life assessment
Drug · Procedure
Lead sponsor
Gary Morrow
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
15
States / cities
Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Sep 11, 2026, 4:14 PM EDT
Completed Phase 3 Interventional

Antibiotic Therapy With or Without G-CSF in Treating Children With Neutropenia and Fever Caused by Chemotherapy

NCT00003739
View directory record Official record
Conditions
Fever, Sweats, and Hot Flashes, Neutropenia, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
filgrastim
Biological
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
206
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Sep 11, 2026, 4:14 PM EDT
Completed Phase 3 Interventional

Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma

NCT00004112
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, CHOP regimen, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate
Biological · Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
2
States / cities
Los Angeles, California • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 22, 2024 · Synced Sep 11, 2026, 4:14 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Weight Regain Treatment Post-Bariatric Surgery

NCT04662801
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Behavioral Weight Loss (BWL), Early Responder: BWL continued, Early Non-responder: BWL continued with medication added
Behavioral · Combination Product
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 12, 2023 · Synced Sep 11, 2026, 4:14 PM EDT
Completed Not applicable Interventional

Environmental Intervention Versus Standard Care to Reduce Pharmacologic Therapy for Asthma

NCT01593111
View directory record Official record
Conditions
Asthma
Interventions
Environmental Intervention
Other
Lead sponsor
Columbia University
Other
Eligibility
6 Years and older
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 3, 2022 · Synced Sep 11, 2026, 4:14 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Genistein in Treatment of Metastatic Colorectal Cancer

NCT01985763
View directory record Official record
Conditions
Colon Cancer, Rectal Cancer, Colorectal Cancer
Interventions
Genistein
Drug
Lead sponsor
Sofya Pintova
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 9, 2019 · Synced Sep 11, 2026, 4:14 PM EDT
Terminated Phase 1 Interventional

Phase I Study of Mitoxantrone and Etoposide Combined With Hydroxychloroquine, for Relapsed Acute Myelogenous Leukemia

NCT02631252
View directory record Official record
Conditions
Leukemia, Acute Myelogenous
Interventions
Hydroxychloroquine, Mitoxantrone, Etoposide
Drug
Lead sponsor
Alison Sehgal, MD, MS
Other
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Sep 11, 2026, 4:14 PM EDT
Terminated Phase 2 Interventional Results available

Treatment With Nab-paclitaxel in Cutaneous SCC

NCT02076243
View directory record Official record
Conditions
Cutaneous Squamous Cell Carcinoma
Interventions
nab-paclitaxel
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 24, 2017 · Synced Sep 11, 2026, 4:14 PM EDT
Terminated Phase 2 Interventional Results available

Alemtuzumab + Rituximab Consolidation in CLL

NCT00771602
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Leukemia
Interventions
Rituximab, Alemtuzumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 22, 2015 · Synced Sep 11, 2026, 4:14 PM EDT
Completed Phase 1 Interventional Results available

Evaluation of a New Anti-cancer Immunotherapy After Chemotherapy in Adult Patients With Acute Myeloid Leukemia (AML)

NCT00725283
View directory record Official record
Conditions
Leukaemia, Myelocytic, Acute
Interventions
GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI)
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
9
States / cities
Tampa, Florida • Baltimore, Maryland • Worcester, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Sep 11, 2026, 4:14 PM EDT
Completed Not applicable Interventional Results available

Programs To Support You During Chemotherapy

NCT02489422
View directory record Official record
Conditions
Depression, Fatigue, Stage IIA Colorectal Cancer, Stage IIB Colorectal Cancer, Stage IIC Colorectal Cancer, Stage IIIA Colorectal Cancer, Stage IIIB Colorectal Cancer, Stage IIIC Colorectal Cancer, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer, Pancreatic Cancer, Esophageal Cancer, Appendix Cancer, Stomach Cancer, Gallbladder Cancer, Liver Cancer, Small Intestine Cancer, Large Intestine Cancer, Anal Cancer, Biliary Tract Cancer, Gastrointestinal Stromal Cancer
Interventions
Laboratory Biomarker Analysis, Questionnaire Administration, Daily Survey Administration, Yoga Skills Training, Attention Control, Actigraphy Assessment
Other · Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
21 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Winston-Salem, North Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced Sep 11, 2026, 4:14 PM EDT
Completed Phase 4 Interventional

Treatment Trial for Psychogenic Nonepileptic Seizures

NCT00835627
View directory record Official record
Conditions
Convulsion, Non-Epileptic, Conversion Disorder, Depression, Stress Disorders, Post-Traumatic, Dissociative Disorders
Interventions
sertraline, CBT-ip, Combined (sertraline + CBT-ip), Standard Care
Drug · Behavioral · Other
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years to 95 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
3
States / cities
Stanford, California • Cincinnati, Ohio • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Nov 9, 2014 · Synced Sep 11, 2026, 4:14 PM EDT
Active, not recruiting Not applicable Interventional

Neuromodulation as a Treatment for Chemotherapy-Induced Peripheral Neuropathy

NCT02573766
View directory record Official record
Conditions
Pain
Interventions
Neurofeedback Training, Electroencephalogram, Pain Scale, Questionnaires
Procedure · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 11, 2026, 4:14 PM EDT
Completed Not applicable Interventional

Validating M.D. Anderson Symptom Inventory (MDASI-GI) in GI Cancer Patients Under Chemotherapy

NCT00849979
View directory record Official record
Conditions
Gastrointestinal Cancer
Interventions
Questionnaire, Interview
Behavioral · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2012 · Synced Sep 11, 2026, 4:14 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Longitudinal Deep Phenotyping of Central Mechanisms in Dysosmia: A Pilot Study Using Electrobulbogram (EBG), Functional MRI (fMRI), and Diffusion-Weighted Imaging (DWI)

NCT07149428
View directory record Official record
Conditions
Respiratory Tract Infection, Smell Disorder, Influenza, Rhinosinusitis, COVID-19, Depression, Parosmia, Hyposomia, Normosomia, Anosmia
Interventions
Not listed
Lead sponsor
National Institute on Deafness and Other Communication Disorders (NIDCD)
NIH
Eligibility
18 Years to 99 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 11, 2026, 4:14 PM EDT